Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

1,557 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016, background): “beyond 2 years) is arbitrary and not validated [12].”
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017, methodology): “Patients were Barcelona Clinic Liver Cancer (BCLC) stage B or C, 23 could not beneﬁ t from resection, local ablation, or chemoembolisation, and must have had documented radiological progression during sorafenib treatment as deﬁ ned in a study-speciﬁ c radiology charter.”
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, methodology): “Indeed, in the current most popular guidelines, surgery is restricted to those patients in the very early or early stages of disease [Barcelona-Clinic Liver Cancer (BCLC) score 0–A] [2, 409].”